International Perfusion Association’s Post

🌟 🌟 THE MORE YOU KNOW 🌟 🌟 A study completed by Pekacka-Egli in 2021 showed that FEES was completed on Day 5 of admission to the post-acute care facility in patients following strokes, 60% experienced favorable diet upgrades. They also showed significantly lower pneumonia rates and a shorter length of stay in this cohort. "Instrumental diagnostics during the early convalescence period of stroke patients lead to clinically relevant changes to the diet and lower rates of pneumonia. Our findings underline the need for regular and qualitative dysphagia diagnostics during stroke rehabilitation." Link to article https://lnkd.in/g4HpYWAM

A great meeting with Caroline Bravo discussing the recent developments in device therapy as rhythm management. Assessment of arrhythmogenic risk in non-ischaemic cardiomyopathy, increasing age of cardiovascular patients, non-cardiac comorbidity, the armentarium of devices and which device for which patient, the increasing role of conduction system pacing, etc. How to educate the community to increase awareness..Boston Scientific #EPeeps #ICD #CIED #arrhythmias

Welcome to MedSynapse, where Dr. Nigar hosts Dr. Ibrahim Jelaidan MBBS, FRCPC, DRCPSC. a distinguished figure in Adult Cardiology, specializing in Advanced Heart Failure, Adult Transplant, and Echocardiography. Today, they dive into anemia's impact on heart failure management: 1. Anemia's Prevalence and Impact: Dr. Jelaidan discusses how anemia affects heart failure patients' prognosis and treatment outcomes. 2. Connecting Anemia and Heart Failure: Exploring the mechanisms linking these conditions and how they worsen each other. 3. Diagnostic and Management Challenges: Dr. Jelaidan highlights the unique difficulties clinicians face in diagnosing and managing anemia in heart failure patients. 4. Evidence-Based Interventions: Iron supplementation, erythropoiesis-stimulating agents, and other therapies are discussed as strategies for managing anemia in heart failure. 5. Guidelines and Trends: Dr. Jelaidan explains how guidelines shape clinical practice and mentions emerging trends and research directions. #anemia #heartfailure #medsynapse #doctornetwork #medicaleducation https://lnkd.in/dj2W7RdW

𝗢𝘂𝗿 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗘𝗻𝗱𝗼𝗭𝗶𝗽™ 𝘀𝘆𝘀𝘁𝗲𝗺 𝗮𝗿𝗲 𝗴𝗮𝗶𝗻𝗶𝗻𝗴 𝘁𝗿𝗮𝗰𝘁𝗶𝗼𝗻 𝗶𝗻 𝘁𝗵𝗲 𝗯𝗮𝗿𝗶𝗮𝘁𝗿𝗶𝗰 𝘀𝘂𝗿𝗴𝗶𝗰𝗮𝗹 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆. Recently featured in 𝗕𝗮𝗿𝗶𝗮𝘁𝗿𝗶𝗰 𝗡𝗲𝘄𝘀, the system has shown an average TBWL of 13.21% at 12 months in our recent multi-center study. These results are making waves, further validating EndoZip as a minimally invasive option for obesity treatment that offers both effective weight loss and improved metabolic health. Proud to be part of a solution that’s transforming patient care. ***** https://lnkd.in/dDaW7wjz

In this on-demand clinical snippet, Dr. Marc Humbert provides an in-depth exploration of managing atypical PAH patients, who often present with complex profiles, including older age, cardiovascular comorbidities, and pulmonary issues.   Click the link in our bio to complete a brief post-test/evaluation and receive AMA, ANCC, or ACPE credit!   #PAH #Pulmonology #CME #continuingmedicaleducation

IgG4-Related Disease is a rare fibro-inflammatory condition with 5 to 10 affected subjects in 100.000 people prevalence that can involve multiple organs at the same time and even lead to organ failure and chronic morbidities. Ospedale San Raffaele is leading the example in how to treat it, with its commitment to do more research and fight it with the IgG4-RD Clinic, a dedicated space with long-experienced immunologists and rheumatologists. The Clinic's team was actually the first to describe IgG4-RD and has so far published more than 100 scientific works. Since IgG4-RD can impact several organs at the same time, the Clinic follows a multidisciplinary approach to grant rant a 360°care to each patient. Being a national and international landmark for IgG4-RD, the Clinic offers professionals the chance to be part of research projects, clinical trials, even benefit from up-to-date off-label treatments, and discuss social and psychological aspects of IgG4-RD. #GruppoSanDonato #GSDHealthMag #ScienceBased #RareDisease

In a recent publication in the European Journal of Heart Failure (November 2023), the impact of cimlanod, a vasodilator, on diuretic response in congestive heart failure patients is explored. The randomized, double-blind trial involved 21 patients receiving loop diuretics. Results revealed that cimlanod, despite its vasodilator properties, led to reduced urine volume post-furosemide compared to the placebo. It notably affected various parameters including sodium excretion, blood pressure, glomerular filtration rate, and plasma volume expansion index. Interestingly, cimlanod's vasodilatory effect increased cardiac output but didn't impact cardiac power index. These findings suggest that while vasodilators like cimlanod may reduce preload and afterload, they can also hinder the efficacy of diuretic agents in heart failure patients. This study underscores the need for a nuanced approach to medication in heart failure management. Read more: https://ow.ly/P3uu50QhZ81 #HeartFailure #Cimlanod #Vasodilators #MedicalResearch #HeartHealth"

Dr. Hassan Alnuaimat, Staff Physician, Pulmonology, Respiratory Institute, alongside Dr. Manyoo Agarwal, Staff Physician, Cardiovascular Medicine, Heart, Vascular & Thoracic Institute at #ClevelandClinicAbuDhabi, take a deep dive into the topic of pulmonary hypertension. In this episode, they discuss how the rare and challenging disease to diagnose, can be effectively addressed through our multidisciplinary approach, significantly improving patients' chances of detection and successful treatment. Watch to learn more. https://lnkd.in/dm7CvmRe

The more Epinephrine in cardiac arrest, the better right? Ok, we know many of you don't believe that. By now many EMS agencies have limited Epinephrine dosing in cardiac arrest to 3 mg. Some have even limited it to 1 mg. A recent study looked at total Epi dosing, specifically in patients receiving eCPR ! 🚑💉 📊 Key Takeaways from the Study: ➡ Researchers classified patients into low (≤3 mg) and high (>3 mg) epinephrine dosage groups. ➡ Patients with a lower epinephrine dose had better neurological outcomes at hospital discharge (55%) compared to the high-dose group (24%). ➡ Higher doses correlated with unfavorable neurological outcomes, with an adjusted odds ratio of 4.6 for poor results, underscoring potential risks of high cumulative doses. 🧠 Conclusions: ➡ Higher cumulative doses of epinephrine (>3 mg) might be linked to worse neurological outcomes post-ECPR. ➡ This data suggests reevaluating epinephrine dosing during resuscitation, especially considering the potential for adverse neurological impacts. Interested in the details or have insights to share from your experiences? 📚 Read the full study here https://lnkd.in/e7fz8Bx7 and let's discuss how we can optimize our protocols for the best patient outcomes! #EmergencyMedicine #CardiacArrest #ECPR #Epinephrine #PatientCare #NeuroOutcomes #EMS

Atrial fibrillation is a condition characterized by irregular heartbeats that can be treated with a procedure called catheter resection, which is a treatment where a catheter is used to remove or "burn" small areas of the heart that cause rhythm problems. Previously, studies on how patient sex affects treatment outcomes for this issue have been inconsistent. However, a new international study, led by the Icahn School of Medicine at Mount Sinai, examined 1,568 patients, both men and women, who underwent a new type of resection called "pulsed-field resection". The results showed that this method was successful in both men and women, with similar success rates (around 76-79%), and it was shown to be safe and effective. This innovative approach offers improved results compared to the traditional methods used previously.   Motivated by these advances, at Cinfa we are also involved in pharmacological treatments which are highly significant in the prevention or treatment of cardiovascular diseases. “At Cinfa we have wanted to place more emphasis and become more involved in research on cardiovascular diseases that will allow us to benefit patients suffering from these pathologies.” reports Alicia Lopez de Ocariz, Chief Scientific Officer at Cinfa Group. https://lnkd.in/dGzdew8x #cardiovasculardiseases #atrialfibrilliation #healthcaremiddleeast